# 1. Financial Performance ## A. Key Figures * Profitability: ₹602 Mn pre-ESOP EBITDA (+25%) · ₹602 Mn adjusted EBITDA (+24.7% YoY, +5.7% QoQ) · 13.6% adjusted EBITDA margin (+126 bps YoY) · ₹176 Mn PAT (+93.7% YoY, +69.7% QoQ) ## B. Revenue Growth * **Divergent Growth Trajectories:** While consolidated revenue grew modestly, **SeQuent’s local currency growth accelerated to 12–14%**, signaling strong underlying momentum. * **Portfolio-Led Growth:** Revenue expansion driven by **successful product launches and favorable mix shift**, particularly in formulations and higher-margin APIs. * **Viyash Growth Constraints:** Top-line growth remains limited by **strategic portfolio pruning**, which has prioritized margin quality over volume. ## C. Profitability Trends * **Structural Margin Expansion:** Significant EBITDA margin improvement achieved despite minimal revenue growth, driven by **exit from unprofitable products** and **introduction of higher-margin offerings**. * **Cost Optimization Gains:** **Gross margin expanded 180 bps YoY** on the back of cost initiatives and mix benefits, with sustained improvement expected across segments. * **Long-Term Margin Targets in Focus:** **Viyash already exceeds 50% gross margins**, while **SeQuent is on track to approach this level**, supported by operational efficiency and new API launches. * **ESOP & One-Off Pressures:** **ESOP and merger-related costs are rising**, posing a near-term overhang on profitability; trajectory for FY26–FY27 under scrutiny. ## D. Balance Sheet Strength * **Resilient Cash Flow Profile:** **Viyash generated strong free cash flow**, supporting deleveraging and providing capacity for post-merger investments. * **Favorable Currency Positioning:** **Majority of API sales in hard currency** and **exports exceed imports**, insulating margins from FX volatility. * **Debt Reduction Roadmap:** Plans to **restructure high-cost SeQuent debt post-merger**, with active evaluation of growth opportunities within a disciplined capital framework. ## E. Cash Flow Generation * **Clean Operating Performance:** No exceptional outflows outside **milestone-based merger costs**, which are expected to persist for **two more quarters**. --- # 2. Product & Therapy Performance ## A. Key Figures * **API Revenue:** **₹100 Cr** (quarterly) (+14% YoY, +21% QoQ) * **Formulation Sales Growth:** +13% YoY · +11% QoQ * **India Formulation Growth:** +8% YoY (Q1 FY’25) * **Oncology Portfolio Value:** **₹15–16 Cr** * **Companion Animal Health Share:** **~5%** of total business ## B. API Business Growth * **Strong Momentum in API Segment:** Robust double-digit quarterly growth driven by improved product mix and competitive margins, with broad-based strength across both albendazole and non-albendazole products. * **Albendazole Demand Remains Resilient:** Sustained high demand for WHO-grade albendazole reinforces leadership position in global tenders, supported by prequalification status. * **Non-Albendazole to Drive Future Growth:** Emerging leadership in non-albendazole APIs signals successful diversification, expected to become the primary growth engine ahead. ## C. Formulation Sales Trends * **Formulations Deliver Consistent Growth:** Core business (75% of total) expanded across all key geographies, reflecting strong commercial execution and market penetration. * **India Growth Despite Seasonality:** Solid performance in domestic markets underpinned by field force expansion and completed capacity upgrades, positioning for sustained brand-led growth. * **Portfolio Optimization Complete:** Pruning of low-margin, low-volume products finalized, removing prior growth drag and enhancing focus on high-value offerings. ## D. Oncology & Animal Health * **Oncology Emerges as Strategic Pillar:** Rapidly scaled therapeutic area with a growing portfolio, supported by recent product filings and a focused development pipeline. * **Companion Animal Expansion Ambition:** Plans to double current **~5%** business share within three years via European distribution expansion and new product launches, including anesthetics. * **US Generic Animal Health Opportunity:** SeQuent well-positioned in high-potential US generics market, with strong audit outcomes validating quality standards. * **Seasonal Drivers in Animal Health:** Rural and dairy-linked demand patterns create volatility, while companion animal API supply gains traction. --- # 3. Geography & Market Mix ## A. Key Figures * **Europe Formulation Growth:** **4% YoY** (+20% QoQ) * **Emerging Markets Growth:** **~25% YoY** * **US Direct API Exposure:** **2–3%** of revenue * **Total US-Linked Exposure:** **17–18%** of revenue ## B. Emerging Markets Growth * **Robust Expansion Momentum:** Emerging markets posted strong double-digit growth, driven by new market entries, export base development, and favorable product mix. * **Strategic Geographic Penetration:** Front-end presence established in **Mexico**, with export hubs in **Turkey and Spain** enhancing regional reach and scalability. * **Sustained Growth Outlook:** Management expects emerging markets to maintain double-digit growth trajectory supported by ongoing internationalization. ## C. Europe & India Performance * **Mixed Regional Trends:** Europe and India delivered single-digit growth, weighed by a high base effect despite recent double-digit momentum from new product launches and vaccine distribution. * **Companion Animal Focus:** Strategic emphasis on companion animal health in Europe, leveraging distribution partnerships and in-house product rollouts. * **Ownership Optionality:** **60% stake** in profitable, high-margin Spanish operations under review for potential full consolidation, though no decision made. ## D. US Market Exposure * **Limited Direct Risk:** Minimal direct API exports to the US (**2–3%** of revenue) insulate near-term performance from regulatory shifts. * **Broader Indirect Exposure:** Total US-linked revenue, including indirect channels and local manufacturing, represents **17–18%** of total exposure. * **Strategic Reorientation:** US formulation and manufacturing assets being repositioned as a competitive lever, particularly in anticipation of potential tariffs. --- # 4. R&D & Product Launches ## A. Key Figures * **Product Filings:** **12** filed globally, including **5 FDFs in the US** * **Regulatory Approvals:** **5 API approvals** (1 US, 3 CEP, 1 Europe) · **1 FDF approval** · **1 EU CEP approval** * **Product Launches:** **2 FDFs in the US** · **2 APIs internationally** ## B. R&D & Collaboration Momentum * **Accelerated Pipeline Activity:** Robust new product filings and approvals each quarter driven by **Viyash-SeQuent R&D integration**, expanding reach across geographies and therapeutic areas. * **Strategic Market Access:** US VMF and **WHO prequalification** for albendazole unlock dual-channel commercialization in both developed and developing markets. ## C. Pipeline Expansion & Synergies * **Sustained Development Pace:** R&D pipeline remains robust with **over 20 products** in various stages, **10–15 expected to enter development/filing in FY '26**. * **Cross-Segment Growth:** Pipeline expansion now includes **animal health**, though progress remains subject to **regulatory timelines**. * **Operational Synergies:** Integration driving **cost improvement** and **manufacturing optimization**, with benefits expected to materialize in coming quarters. --- # 5. Manufacturing & Capacity ## A. Facility Utilization * **Headline:** Manufacturing synergies underway with product transfers to unlock idle capacity; full benefits expected over **12–24 months** due to regulatory timelines. * **Headline:** Network optimization poised to drive gross margin improvements, supported by **60–65% capacity utilization at Viyash** and available capacity at one SeQuent site. * **Headline:** Turkey facility now serves as strategic export hub for Europe, with upcoming product launches enabled by EU GMP approval. ## B. GMP Approvals * **Headline:** Spanish manufacturing facility secured **GMP approval**, unlocking new product introductions in coming quarters. * **Headline:** Turkey-based injectables plant received **EU GMP certification**, enabling expanded exports of animal health injectables into European markets. ## C. Synergy Integration * **Headline:** Synergies between SeQuent and Viyash are exceeding expectations, with R&D integration complete and joint product development active. * **Headline:** Integration advancing across **four key pillars**, including procurement optimization and alignment on long-term strategic and organizational direction over the next **3–5 years**. * **Headline:** CDMO emerges as strategic growth vector, with dedicated team formation underway and **initial engagements active**; full strategy expected in **1–2 quarters**. * **Headline:** Viyash brings proven CDMO capabilities in **analytical, EHS, and operations**, currently serving **8 of the top 10 innovator companies**. --- # 6. Regulatory & Compliance Risks ## A. Key Figures * **Audit Outcomes:** **5 US FDA audits** passed with **EIS ratings** in last 12–15 months · **30+ customer audits** successfully managed in quarter ## B. Audit Outcomes * **Exemplary Compliance Track Record:** Demonstrated regulatory resilience through flawless execution across multiple high-stakes inspections, including simultaneous FDA audits. * **Strong Quality Culture Validated:** EIS ratings from US FDA and successful customer audit volume reinforce leadership in quality systems and readiness for global markets. ## C. Biosecure Act Impact * **Strategic Regulatory Positioning:** Despite political uncertainty, company sees **more opportunities than risks** from evolving US policy landscape, including the Biosecure Act. * **Proactive Preparedness:** Facilities are being aligned with global standards; multi-year timeline (3–5 years) for Biosecure Act implementation provides buffer for full compliance readiness. --- # 7. Guidance & Outlook ## A. Key Figures * **API Quarterly Run Rate Target:** **₹100 Cr** (sustainable, merger- and R&D-supported) * **Full-Year Growth Trend:** **Double-digit** secular growth expected despite quarterly volatility * **PAT vs. EBITDA Growth:** **PAT growth to outpace EBITDA growth** (no specific PAT guidance given) ## B. Margin Expectations * **Strategic Clarity Ahead:** A detailed investor presentation on margin enhancement and strategic direction expected within the next two quarters. ## C. Merger Timeline * **Merger on Track:** The proposed merger with Viyash Life Sciences is progressing as planned, with CCI, SEBI, and stock exchange approvals secured. * **Advanced Regulatory Stage:** NCLT filings completed; shareholders’ and creditors’ meeting scheduled for **August 30, 2025**, keeping integration on schedule. * **Early Integration Underway:** Substantial P&L and balance sheet improvements anticipated within the first few quarters post-merger, with integration already in motion. ## D. Growth Projections * **New Growth Phase:** Company has transitioned from consolidation to accelerated growth and operational transformation, enabling investment in core and new businesses. * **Expansion Ambitions:** Evaluating more aggressive expansion in the companion animal segment within the next year to drive scale.